BD Live! powered by the Relay Innovation Engine augments business development efforts in both breadth and depth using a web-based analytics approach to identify promising drug candidates from academic research institutions and early-stage biotechnology companies.
The Relative Asset Value Index (RAVI) utilized in BD Live! includes multiple factors that contribute to the value of early-stage technologies. BD Live! powered by the Relay Innovation Engine evaluates pre-clinical technologies from over 500 academic research institutes, and phase II/III clinical trial candidates from 2500 biotechnology companies around the world.
BD Live! powered by the Relay Innovation Engine also incorporates key decision support metrics such as strength of intellectual property, market potential, and scientific trends. These features allow BD Live! powered by the Relay Innovation Engine to confer immediate benefits to in-licensing efforts, increasing both efficiency and effectiveness.
In-licensing groups using the Relay database can expect:
- Greater reach, with evaluation of technologies from over 500 University licensing offices and 2500 biotechnology companies
- Improved focus, with technologies of interest ranked by key licensing criteria
- Rapid go/no-go decisions limiting time and effort required by licensing teams
- Increased time spent on high-potential candidates
The result is a broader, deeper in-licensing program, making more efficient use of the existing business development group.
Click to learn more about what business problems Relay sovles
